NCT07187908View on ClinicalTrials.gov

Efbemalenograstim Alfa for Primary/Secondary Prevention in Patients With Solid Tumors at High Risk for Febrile Neutropenia (FN) or Intermediate Risk of Chemotherapy Regimens Associated With Other Risk Factors in FN

PHASE2RecruitingINTERVENTIONAL
Enrollment

1,076

Participants

Timeline

Start Date

January 1, 2025

Primary Completion Date

October 31, 2026

Study Completion Date

October 31, 2027

Conditions
Primary/Secondary PreventionHigh Risk for Febrile Neutropenia of Chemotherapy RegimensIntermediate Risk of Chemotherapy Regimens Associated With Other Risk Factors in Febrile Neutropenia
Interventions
DRUG

Efbemalenograstim alfa Injection

The patients with solid tumor who were at high risk for febrile neutropenia or intermediate risk of chemotherapy regimens associated with other risk factors in febrile neutropenia would be injected Efbemalenograstim alfa for primary/secondary prevention.

Trial Locations (1)

450003

RECRUITING

The Henan cancer hospital, Zhengzhou

All Listed Sponsors
collaborator

West China Hospital

OTHER

lead

Henan Cancer Hospital

OTHER_GOV